Loading...
01/11 03:33
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call highlights strong financial performance with record operating margins and revenue growth, particularly in cardiac interventions. Despite a decline in China sales and tariff impacts, the company has raised its operating margin guidance and expects sustainable growth in key areas. While there are uncertainties, such as the WRAPSODY filing delay, management's confidence in overcoming these challenges and their strategic focus on acquisitions and market expansion suggest a positive outlook. Given the company's market cap and the positive sentiment, a stock price increase of 2% to 8% is likely.
Total Revenue $382.5 million, up 13% year-over-year on a GAAP basis, and up 12.5% year-over-year on a constant currency basis. The increase was driven by a 6.7% constant currency organic growth, exceeding the 6% high end of the range outlined in the second quarter guidance.
Non-GAAP Operating Margin 21.2%, increased nearly 109 basis points year-over-year. This represents the highest non-GAAP operating margin performance in any quarter in the company's history as a public company.
Non-GAAP EPS 10% growth year-over-year, exceeding the high end of expectations.
Free Cash Flow $70 million, an increase of 20% year-over-year. This performance was attributed to the team's continued hard work and commitment to strategic objectives.
Cardiovascular Segment Revenue 10% growth year-over-year, with organic constant currency growth of 6.8%.
Endoscopy Segment Revenue 81% growth year-over-year, with organic constant currency growth of 1%.
Cardiac Intervention Product Sales 23% growth year-over-year, with organic constant currency growth of 10%.
Peripheral Intervention Products 6% growth year-over-year.
Custom Procedure Solutions Products 6% growth year-over-year, exceeding the high end of expectations.
OEM Products 4% growth year-over-year, slightly below expectations due to softer demand outside the U.S.
U.S. Revenue 17% growth year-over-year on a constant currency basis, with organic constant currency growth of 10%.
International Revenue 7% growth year-over-year, with organic constant currency growth of 2%. Sales in APAC exceeded expectations, EMEA was in line, and Rest of the World was slightly below expectations.
Gross Margin 53.2%, up 167 basis points year-over-year. The increase was driven by lower tariff impact, favorable product and geographic revenue mix, and pricing improvements.
Operating Income $80.9 million, a 19% increase year-over-year. Operating margin was 21.2%, up 109 basis points year-over-year.
Net Income $61 million, or $1.01 per share, compared to $53.8 million, or $0.92 per share, in the prior year period.
Acquisition of Biolife Delaware, L.L.C.: Merit acquired Biolife Delaware for $120 million. Biolife manufactures patented hemostatic devices, StatSeal and WoundSeal, which address a $350 million global market. These products complement Merit's portfolio and are expected to drive growth.
WRAPSODY CIE: The WRAPSODY CIE, a novel dialysis maintenance product, was launched in the U.S. It is priced at a premium and has received FDA Breakthrough Designation. Efforts are ongoing to secure reimbursement for inpatient and outpatient settings.
Geographic Revenue Growth: U.S. sales grew 17% year-over-year, while international sales grew 7%. APAC exceeded expectations, EMEA met expectations, and Rest of the World slightly underperformed.
Revenue and Profitability: Q2 revenue was $382.5 million, up 13% year-over-year. Non-GAAP operating margin reached 21.2%, the highest in company history. Free cash flow increased 20% to $70 million.
Product Segment Performance: Cardiovascular segment grew 10%, driven by 23% growth in cardiac intervention products. Endoscopy segment grew 81%. Organic growth in Cardiovascular was 6.8%.
CEO Succession: Martha Aronson will become CEO on October 3, 2025, as part of a planned succession strategy. Current CEO Fred Lampropoulos will remain Chairman.
Reimbursement Strategy for WRAPSODY CIE: Efforts to secure reimbursement for WRAPSODY CIE in outpatient settings faced a two-quarter delay. CMS proposed a $3,770 add-on payment for inpatient procedures, effective October 1, 2025.
Global Macro Environment: The company acknowledges challenges related to the dynamic and uncertain global macro environment, which could impact operations and financial performance.
Reimbursement Strategy for WRAPSODY CIE: A two-quarter delay in securing add-on reimbursement in the outpatient setting for WRAPSODY CIE has been identified, which could impact revenue and adoption rates in the U.S. market.
China Market Performance: Sales in China decreased by 6%, attributed to the broader macro environment, which could affect overall international revenue growth.
OEM Sales Outside the U.S.: Softer-than-expected performance in sales to OEM customers outside the U.S. due to macroeconomic factors, potentially impacting revenue growth.
Regulatory and Reimbursement Challenges: The company faced issues with its application for new technology APC assignment for WRAPSODY CIE, leading to delays and potential revenue impacts.
Tariff and Trade Policy Risks: Potential changes in tariffs and trade policies could impact manufacturing costs and overall profitability.
Total Revenue Guidance for 2025: GAAP net revenue growth of 10% to 11% year-over-year, with Cardiovascular segment growth of approximately 9% to 10% and Endoscopy segment growth of approximately 32% to 34%. Excluding foreign currency impacts, constant currency revenue growth is expected to be 9.7% to 10.6%.
U.S. Revenue Growth: Midpoint of total constant currency growth assumes 12% growth in the U.S. and 8% growth outside the U.S. International growth includes low double-digit growth in EMEA, mid-teens growth in Rest of the World, and approximately 2% growth in APAC.
WRAPSODY CIE Revenue: U.S. revenue from WRAPSODY CIE is projected to be $2 million to $4 million for 2025, reflecting a two-quarter delay in securing add-on reimbursement in the outpatient setting. Long-term market potential remains unchanged.
Non-GAAP EPS Guidance for 2025: Updated range of $3.52 to $3.72, reflecting better-than-expected performance in the first half of 2025 and adjustments for higher interest expense and tax rate assumptions.
Non-GAAP Operating Margins: Expected to range between 19% to 20% for 2025, up from prior guidance of 17.6% to 18%, driven by lower tariff impacts and stronger-than-expected performance.
Free Cash Flow and Capital Expenditures: Free cash flow of at least $150 million in 2025, with capital expenditures expected to be $90 million to $100 million.
Third Quarter 2025 Revenue Growth: Expected GAAP revenue growth of 8.6% to 10.5%, with constant currency growth of 8% to 9.8%. Organic constant currency growth is projected at 4% to 5.6%.
Third Quarter 2025 Non-GAAP EPS: Expected to range between $0.76 to $0.85, compared to $0.86 in the prior year.
The selected topic was not discussed during the call.
The earnings call summary reflects a positive outlook with strong financial metrics, optimistic guidance, and strategic focus on growth. The Q&A section confirmed strong free cash flow and potential for acquisitions, while addressing concerns about expenses and market dynamics. The company's clear strategy for growth, including WRAPSODY and CryoBalloon C2, supports a positive sentiment. Given the market cap, the stock price is likely to react positively, within the 2% to 8% range, over the next two weeks.
The earnings call highlights strong financial performance with record operating margins and revenue growth, particularly in cardiac interventions. Despite a decline in China sales and tariff impacts, the company has raised its operating margin guidance and expects sustainable growth in key areas. While there are uncertainties, such as the WRAPSODY filing delay, management's confidence in overcoming these challenges and their strategic focus on acquisitions and market expansion suggest a positive outlook. Given the company's market cap and the positive sentiment, a stock price increase of 2% to 8% is likely.
The earnings call highlights mixed results: strong revenue growth and margin improvements, but a decline in free cash flow and no shareholder return plan. The Q&A reveals management's lack of clarity on certain risks, such as tariffs and demand in China. Despite strong earnings and optimistic guidance, the absence of a buyback or dividend plan, along with financial uncertainties, tempers positive sentiment. The company's mid-cap size suggests moderate stock price movement, leading to a neutral prediction.
The earnings call summary presents a mixed picture. While financial performance and gross margins show strength, the impact of tariffs and lack of a share repurchase plan are concerning. The Q&A highlighted management's evasiveness on specific issues, which could lead to uncertainty. The market cap of $4.8 billion suggests moderate sensitivity to these factors. Consequently, the stock price is likely to remain stable, resulting in a neutral prediction (-2% to 2%) over the next two weeks.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
